bi 1026706
Small moleculeexperimental
Clinical trial activity
9 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2013 (NCT01763333)
Timeline
Indications
Mechanism of action
- B1 bradykinin receptorINHIBITOR
BDKRB1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bi 1026706
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02652416 | Phase 1 | Sep 1, 2016 | Boehringer Ingelheim |
| NCT02732951 | Phase 2 | May 9, 2016 | Boehringer Ingelheim |
| NCT02657408 | Phase 1 | Mar 1, 2016 | Boehringer Ingelheim |
| NCT02642614 | Phase 1 | Jan 1, 2016 | Boehringer Ingelheim |
| NCT02513446 | Phase 1 | Sep 1, 2015 | Boehringer Ingelheim |
| NCT02126826 | Phase 1 | May 1, 2014 | Boehringer Ingelheim |
| NCT02084511 | Phase 1 | Mar 1, 2014 | Boehringer Ingelheim |
| NCT02037165 | Phase 1 | Jan 1, 2014 | Boehringer Ingelheim |
| NCT01763333 | Phase 1 | Jan 1, 2013 | Boehringer Ingelheim |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 9 | 9 | 2 | 2013 |
1 organizations
Page 1 / 1